Spectral AI

Dallas, TX All United States companies → — Founded 2009

Imaging AI Specialist Medical Device / Hardware Specialty-Focused AI

Dermatology General Surgery Plastic Surgery

Public (NASDAQ: MDAI) — BARDA contract up to $150.0M ($86.6M committed to date); $12.5M equity advance (2024); up to $15.0M debt financing + $2.7M equity (2025)

Claim this company

Products

SPECTRALMD DEEPVIEW WOUND IMAGING SYSTEM

Spectral AI, Inc.

Dermatology AI

The Spectral AI DeepView Wound Imaging System uses multispectral imaging and proprietary AI algorithms to provide immediate, objective predictions of wound healing potential, aiding clinicians in faster, more accurate treatment decisions.

Contact for pricing

See all 1 product →

About Spectral AI

Spectral AI is an artificial intelligence company dedicated to advancing predictive medical diagnostics, with a primary focus on wound care. Their core innovation is the DeepView® System, a non-invasive technology that combines proprietary AI algorithms with multispectral imaging (MSI). This system is designed to provide physicians with objective, real-time insights into tissue viability by identifying characteristics invisible to the human eye at the initial presentation of a wound. The DeepView System delivers a binary prediction on a wound’s capacity to heal or not heal by a specified future time point, thereby enabling faster and more accurate treatment decisions.

For healthcare professionals, the DeepView System represents a significant leap in managing complex wounds, particularly thermal burns and diabetic foot ulcers (DFUs). By offering objective data on healing potential, it empowers clinicians to optimize treatment plans, potentially reducing the need for unnecessary procedures and enhancing workflow efficiency in critical care settings such as emergency departments, trauma centers, and burn units. Clinical studies have demonstrated the DeepView System’s high accuracy in predicting burn wound healing, often surpassing traditional clinical judgment in identifying non-healing tissue. The technology aims to improve patient outcomes through earlier, more informed interventions and contribute to a reduction in overall healthcare costs associated with prolonged wound management.

Focus Areas

Medical diagnostics Predictive AI Wound care Burn assessment Diabetic foot ulcer assessment Multispectral imaging AI algorithms

Business Intelligence

Key Investors	Avenue Venture Opportunities Fund II, L.P. (Avenue Capital Group), BARDA (U.S. Government)
Partnerships	BARDA (Biomedical Advanced Research and Development Authority), National leaders in burn care, American Burn Association, PolyNovo
Acquisitions	Rosecliff Acquisition I
Technology	DeepView® System, AI-driven wound diagnostics platform, Multispectral Imaging (MSI), Proprietary AI algorithms, Deep learning, "Seeing the Unknown®"
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Medical Diagnostics & Predictive AI

Spectral AI's DeepViewu00ae System provides objective, immediate, and highly accurate 'Day One' predictions of wound healing potential. This AI-driven platform aims to revolutionize medical diagnostics by offering insights not visible to the human eye.

Wound Care & Burn Assessment

The DeepViewu00ae System has demonstrated 92% accuracy in predicting if a burn wound will heal, significantly outperforming traditional visual assessments by surgeons (which average ~70% accuracy). It aids in determining the necessity of surgical interventions and has received FDA Breakthrough Device Designation for burn indications.

Diabetic Foot Ulcer Assessment

For diabetic foot ulcers (DFUs), DeepViewu00ae achieves 86% accuracy in predicting if a wound will close by 50% in four weeks, enabling earlier and more informed treatment decisions compared to the traditional 'wait and see' approach.

Multispectral Imaging

The core technology involves multispectral imaging (MSI), which captures multiple wavelengths of light from the visible blue field to the deep infrared spectrum. This non-invasive method measures reflectance to classify tissue viability and extract millions of data points from each image.

AI Algorithms & Proprietary Data

Spectral AI utilizes proprietary AI algorithms trained and tested against a vast, clinically validated database of over 340 billion data points, including the world's largest burn biopsy tissue database. This extensive training allows for robust and accurate predictions.

Physician Tip

For physicians, Spectral AI's DeepViewu00ae System offers a transformative tool for wound management. It provides objective, immediate, and highly accurate 'Day One' predictions of wound healing potential, reducing the subjectivity and variability inherent in traditional visual assessments. This enables earlier and more precise treatment decisions, potentially leading to improved patient outcomes, reduced unnecessary surgeries, shorter hospital stays, and lower healthcare costs. The non-invasive nature of the multispectral imaging and the rapid AI analysis (image acquisition in 0.2 seconds, prediction in 20-25 seconds) streamline workflow and support proactive intervention, especially in critical care environments like burn centers and emergency departments.

The DeepViewu00ae System is designed as a mobile, cart-based platform, allowing for exceptional mobility within healthcare settings. While the importance of integrating AI with electronic health records for comprehensive diagnostic insights is recognized, specific details on current direct EHR integrations are not explicitly detailed in the provided information. The system's output is engineered to assist physicians in making informed decisions, suggesting it can complement existing clinical workflows.

At a glance

Founded 2009

HQ Dallas, TX · United States

Team size 65

CEO Vincent Capone

Funding Public (NASDAQ: MDAI) — BARDA contract up to $150.0M ($86.6M committed to date); $12.5M equity advance (2024); up to $15.0M debt financing + $2.7M equity (2025)

FDA clearances 2 (estimated)

Products 1

Products by Spectral AI

1 product in the directory

SPECTRALMD DEEPVIEW WOUND IMAGING SYSTEM

Spectral AI, Inc.

Dermatology AI

Contact for pricing

What the Web Says

Spectral AI is a Dallas-based company specializing in AI-driven medical diagnostics, particularly known for its DeepView Wound Imaging System. This non-invasive tool uses multispectral imaging and AI to predict wound healing potential, aiming to provide objective assessments for conditions like burns and diabetic foot ulcers. The company has received recognition, including being named one of TIME's World's Top HealthTech Companies for 2025. While product reviews highlight its innovative technology and potential to revolutionize wound care, employer reviews are mixed, with some concerns about company culture and management practices.

Overall: Mixed

Strengths

DeepView system offers accurate, objective, and immediate assessment of wound healing potential, outperforming traditional clinical judgment in burn assessments.
The technology is non-invasive, fast, and practical for real-world clinical settings, improving treatment decisions and potentially reducing unnecessary surgeries and healthcare costs.
Strong potential for market disruption and creation of a new diagnostic market for AI wound diagnostics, with no current comparable competitors.
Positive and innovative company culture, with opportunities for personal and professional growth, as reported by some employees.
Significant government funding and strong intellectual property with approved U.S. and international patents.
Management team is experienced and there are existing real-world hospital partnerships.

Limitations

Some employee reviews indicate a deteriorating company culture, with concerns about managers pushing for excessive work, managing out employees, and discouraging casual conversation.
Reported issues with pay being perceived as low by some employees.
The company's stock is considered a speculative bet, with its commercial rollout still needing to prove company-generated projections.
Limited historical data and a learning curve for non-technical users in some AI visibility tools, though this is not directly about Spectral AI's product.
Specificity in identifying non-healing wound areas was lower for DeepView compared to physicians, though this was attributed to physicians' conservative assessments.
No reviews found on G2, Glassdoor, or Capterra directly for Spectral AI's DeepView product or as an employer, with G2 listing it as an unclaimed profile.

Based on reviews from: Elion, Spectral AI Careers Page, Reddit (r/SpectralAI, r/pennystocks), MedTech Dive, TIME, Danelfin, Spectral AI (Predictive Analytics page), Traders Union, Medical Product Outsourcing, Indeed.com

Last updated: 2026-07-19

Videos

News, demos, and interviews about Spectral AI.

Loading videos...

Videos load interactively. If none appear, search YouTube for Spectral AI →

View all on YouTube

Press & Coverage

GlobeNewswire

Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepViewu00ae System for Burn Indication

Spectral AI appointed Darcy Bajko as Chief Commercial Officer to lead the global commercial launch of its FDA-cleared DeepViewu00ae System for burn indication, effective July 31, 2026. This move signifies the company's shift from product development to commercial execution following FDA De Novo Classification in May 2026.

2026-07

Investing.com

Spectral AI Receives FDA De Novo Clearance for DeepViewu00ae System for Burn Indication

Spectral AI announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView System, allowing the company to begin commercial distribution in the United States. The DeepView System is a non-invasive medical device that uses multispectral imaging and an AI algorithm to assess the healing potential of burn wounds.

2026-05

GlobeNewswire

Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepViewu00ae System

Spectral AI received $31.7 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of additional features for its DeepViewu00ae System. This non-dilutive funding supports the AI-driven burn wound imaging technology as the company awaits FDA market authorization.

2026-03

Spectral AI, Inc. Investor Relations

Spectral AI Announces 2025 Fourth Quarter and Full Year Financial Results and Introduces Revenue Guidance for 2026

Spectral AI announced its financial results for Q4 and full year 2025, providing an update on the commercialization of its DeepViewu00ae System and forecasting approximately $18.5 million in revenue for 2026. The company reported a net income of $0.6 million for Q4 2025, a significant improvement from a net loss in Q4 2024.

2026-03

Spectral AI, Inc. Investor Relations

Spectral AI raises $7.6 Million of Additional Growth Capital

Spectral AI announced the pricing of a $7.6 million offering to secure additional growth capital for the expansion and development of its DeepViewu00ae System. The financing includes the issuance of common stock and pre-funded warrants, aiming to support clinical indications and prepare for commercial readiness in 2026.

2025-10

Spectral AI, Inc. Investor Relations

Spectral AI Announces Submission to FDA of its DeepViewu00ae System

Spectral AI submitted its De Novo 510k marketing clearance application to the FDA for its AI-driven DeepViewu00ae System, a non-invasive device that uses multispectral imaging and AI to assess burn wound healing potential. This submission is a major step towards bringing the diagnostic device to market in the United States.

2025-06

MedTech Dive

Spectral AI algorithms beat physicians in burn tissue assessments

Spectral AI's DeepView System outperformed burn physicians in identifying non-healing tissue in a burn validation study, achieving 86.6% sensitivity at an image-wise level compared to physicians' 40.8%. The company plans to file these results with the FDA by mid-2025 and aims for a product launch in 2026.

2025-03

Journal of Burn Care & Research

Clinical Investigation of a Rapid Non-invasive Multispectral Imaging Device Utilizing an Artificial Intelligence Algorithm for Improved Burn Assessment

This peer-reviewed article details a clinical investigation into Spectral AI's rapid non-invasive multispectral imaging device, demonstrating its feasibility for detecting non-healing burn tissue. The study suggests that multispectral imaging combined with AI could significantly aid in the earlier diagnosis of indeterminate burns.

2023-04

Frequently Asked Questions

What is Spectral AI's DeepViewu00ae System and how does it utilize AI and multispectral imaging for medical diagnostics in wound care?

Spectral AI's DeepViewu00ae System is a predictive diagnostic device that combines multispectral imaging with proprietary AI algorithms to provide objective, immediate assessments of a wound's healing potential. This technology allows clinicians to 'See the Unknownu00ae' by analyzing tissue viability and characteristics not visible to the human eye, aiding in faster and more accurate treatment decisions for conditions like burns and diabetic foot ulcers.

How accurate is the DeepViewu00ae System in predicting healing potential for burn wounds and diabetic foot ulcers, and what clinical benefits does it offer?

The DeepViewu00ae System has demonstrated high accuracy, achieving 92% in predicting whether a burn wound will heal on Day One, and 86% accuracy in predicting if a diabetic foot ulcer will close by 50% in four weeks. This predictive capability aims to reduce waiting times, minimize patient costs, lower infection probabilities, and enable earlier advanced wound care interventions, significantly improving patient outcomes.

What is the regulatory status of Spectral AI's DeepViewu00ae System, particularly regarding FDA clearance and international compliance?

Spectral AI's DeepViewu00ae System for burn indication received FDA Breakthrough Device Designation in 2017 and a De Novo 510(k) marketing clearance application was submitted to the FDA in June 2025. The DeepView SnapShotu00ae Wound Imaging System has also achieved UKCA marking for use in the United Kingdom and received Class 1 medical device classification with the U.S. FDA.

What is Spectral AI's business model, including pricing, and what kind of support is available for integrating the DeepViewu00ae System?

Spectral AI plans to offer the DeepViewu00ae system as a capital equipment purchase with an annual base subscription, and a per-scan reimbursement-based fee. While specific details on support are not extensively disclosed, the company provides clinical validation studies and implementation support to help integrate the system into existing clinical workflows and electronic health records.

What are Spectral AI's key partnerships and what is the company's financial stability for long-term collaboration?

Spectral AI has significant partnerships with the U.S. Government, including over $250 million in contracts from BARDA and collaborations with the Defense Health Agency (DHA) and USAMMDA. While the company has secured substantial non-dilutive government funding and debt financing, it has also reported historical net losses and negative shareholder equity, indicating a growth-focused stage with ongoing financial management.

What measures does Spectral AI take to ensure the reliability and ethical considerations of its AI algorithms in clinical decision-making?

Spectral AI's AI algorithms are trained and tested against a large, proprietary, and clinically validated database of wound images and pathology data, which includes over 340 billion data points for burn assessment. The pursuit of FDA regulatory pathways like Breakthrough Device Designation and De Novo classification indicates a commitment to rigorous validation and addressing the novel aspects of their AI technology for safe and effective clinical use.

Related Companies

Suggest an Edit →